Cellcept (Oral)

Embryofetal Toxicity, Malignancies and Serious InfectionsUse during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning.Increased risk of development of lymphoma and other malignancies, particularly of the skin.Increased susceptibility to infections, including opportunistic infections and severe infections with fatal outcomes .

Embryo-Fetal Toxicity, Malignancies, and Serious InfectionsUse during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning.Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe mycophenolate sodium. Patients receiving mycophenolate sodium should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.Increased risk of development of lymphoma and other malignancies, particularly of the skin, due to immunosuppression.Increased susceptibility to bacterial, viral, fungal, and protozoal infections, including opportunistic infections .